Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma with a Buy and maintains $4 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Earnings Call Summary | Arbutus Biopharma(ABUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arbutus ended Q1 2024 with cash, cash equivalents, and investments of arou
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
Arbutus Biopharma Announces Chief Scientific Officer's Retirement
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, Vs. Street Est of $3.7M
07:34 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M
Arbutus Biopharma 1Q Loss $17.9M >ABUS
Arbutus Biopharma 1Q Loss $17.9M >ABUS
Press Release: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: A
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virol
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement case against Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine.The
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma (NASDAQ:ABUS) impacted investor sentiment. Arbutus has received permission to pursue its patent inf
Arbutus Biopharma Price Target Maintained With a $4.00/Share by JMP Securities
Arbutus Biopharma Price Target Maintained With a $4.00/Share by JMP Securities
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
JMP Securities analyst Roy Buchanan reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and maintains $4 price target.
Unpleasant Surprises Could Be In Store For Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares
You may think that with a price-to-sales (or "P/S") ratio of 28.9x Arbutus Biopharma Corporation (NASDAQ:ABUS) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in th
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Arbutus Biopharma Up Over 14%, on Pace for Largest Percent Increase Since December 2021 -- Data Talk
Arbutus Biopharma Corporation (ABUS) is currently at $2.88, up $0.36 or 14.29% --Would be highest close since Feb. 28, 2024, when it closed at $2.88 --On pace for largest percent increase since Dec.
Arbutus Biopharma Jumps After Patent Victory in Fight With Moderna
No Data